The Thai efficacy trial of a prime–boost regimen comprising a canarypox vector (ALVAC-HIV, Sanofi Pasteur) followed by a gp120 subunit in Alum (AIDS VAXB/E, Global Solutions for Infectious Diseases) showed a statistically significant trend towards preventing HIV infection in an at-risk population [33]. Here, ITIH4 is linked to HIV infectious disease.